The Medicines Agency warns of a “risk of dosage error”.
Alerted by the laboratory which manufactures and markets them, the Medicines Agency (ANSM) reported a defect in certain specialties of Doliprane, a famous medicine based on paracetamol indicated in cases of pain or fever (headaches, flu-like symptoms, dental pain, aches, etc.). “The fault only concerns the pipette“, we can read in the press release of May 15, on which there may be an absence of graduation which could lead to a “risk of dosage error”. On the other hand, the integrity and quality of the syrup contained in the bottle remain intact.
This printing defect does not concern all forms of Doliprane. Only boxes of the specialty Doliprane 2.4% in oral suspension intended for infants and children (from birth to approximately 9 years old) are concerned. These are the famous pale pink boxes. In total, more than 1.3 million boxes are affected, the lot numbers of which are as follows:
- 3KLR12D1
- 3KLR13D2
- 3KLQ70DU
- 3KLQ69DT
- 3KLR14D3
- 3KLQ71DV
- 3KLQ72DW
This notice is preventive: no pharmacovigilance cases linked to this printing defect have been reported to date in France and these batches are, at this stage, not recalled. However, as a precaution, if you have a box of Doliprane 2.4% oral suspension, check that the pipette is correctly graduated. If so, you can use it safely. If this is not the case, return the box to a pharmacy, it will be exchanged for you by the pharmacist. Do not use the non-graduated pipette or the pipette of another medication, to avoid risking a dosage error. If you buy a box of Doliprane 2.4%, oral suspension, from one of these batches, the pharmacist will check the condition of the pipette in front of you at the time of delivery.
In this context, the manufacturer of the pipettes (the Opella Healthcare France laboratory) claims to have taken measures to ensure that new batches of Doliprane do not/no longer contain this printing defect.